NCT07920757Active, not recruiting
Multi-omics Profiling of Relapsed Extranodal Natural Killer (NK)/T-cell Lymphoma
A Retrospective Observational Study of Tumour Microenvironment Remodelling and Clonal Architecture in Relapsed or Refractory Extranodal NK/T-cell Lymphoma Using Single-Cell, Spatial and Genomic Profiling
Source: ClinicalTrials.gov · Last updated 6 Nov 2026
Brief summary (registry, in English)
This retrospective observational study characterises the tumour immune microenvironment and clonal architecture of relapsed or refractory extranodal NK/T-cell lymphoma (ENKTCL). Archival tumour tissue and blood samples collected during routine care are profiled by single-cell RNA sequencing, T-cell and B-cell receptor repertoire sequencing, whole-exome sequencing, and spatial transcriptomics. The study examines how immune and stromal cell states, clonal composition and spatial organisation relate to response to programmed cell death protein 1 (PD-1) blockade and to subsequent relapse.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 27 Oct 2026
- Start date
- 27 Sept 2022
- Primary completion date
- 30 Dec 2028
- Lead sponsor
- Fujian Medical University Union Hospital
- Diseases
- Childhood cancers
- NCT number
- NCT07920757
What you commit to
- Study type: Observational
- Planned participants: 50
- From 27 Sept 2022 to the primary completion date, 30 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Insufficient tissue or nucleic acid quality for the planned profiling assays
- Incomplete clinical records precluding assessment of response or outcome
Who the study is looking for
- Histologically confirmed extranodal NK/T-cell lymphoma, nasal type
- Relapsed or refractory disease after at least one prior line of therapy, or archival tissue available from a relapse episode
- Archival formalin-fixed paraffin-embedded tumour tissue and/or peripheral blood available for molecular profiling
- Received PD-1 or PD-L1 blockade as part of routine care at any point in the disease course
- Written informed consent for the use of residual clinical specimens in research, or a waiver of additional consent granted by the institutional ethics committee
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fujian Medical University Union Hospital | Fuzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.